Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
about
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert GroupGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursMetronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinomaNeuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewGastroenteropancreatic high-grade neuroendocrine carcinomaManagement of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphologyNeuroendocrine pancreatic tumors: guidelines for management and updatePathologic research update of colorectal neuroendocrine tumorsGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsNeuroendocrine tumors of the gastro-entero-pancreatic systemNeuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasReview article: current status of gastrointestinal carcinoids.Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategyNeuroendocrine carcinoma of the sigmoid colon: report of a case.Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Biologics in gastrointestinal and pancreatic neuroendocrine tumorsOutcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETsLarge cell neuroendocrine carcinoma of the rectum presenting with extensive metastatic disease.Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Gastric neuroendocrine tumours.Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinomaRelationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors.Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.Gastric endocrine cell carcinoma with long-term survival developing metachronous remnant cancerNANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
P2860
Q24674315-AF5DA1DC-656A-49B5-B19A-84F841AC0997Q24685837-510AEEFB-F348-4D13-A5E9-464A39E6742BQ26753070-8CE5F628-B141-4F1B-8928-FCD87A9E8F92Q26768483-24E6A96F-982F-461B-977F-B0FB45582DA0Q26998392-C135F78F-5A73-4B79-B99A-7E7C2672C300Q28078501-57FED5E2-2F72-456B-AA75-47FF5F96F12EQ28256132-0DC19AF2-5898-4294-AD30-E0A006B3D8AAQ28279323-B5EBE349-FF44-44C1-891F-A482C3EBFE34Q28290833-B6F89062-7086-47CC-819A-F6410E0FF2F6Q28294432-4A08C190-096A-4946-9BDC-C82D248242F3Q30238552-1F093289-98FA-4BFE-A812-09E1852C135CQ30249051-4AFE9DC0-3F66-48A6-BEDB-AAEFCD9E6610Q30364864-7CF85221-1ACB-4F84-82E8-20E8EC8DF47BQ33394763-804756DF-622A-47FD-8225-1990130F0107Q33417320-1DA967C6-A7FC-4DFA-8400-FF6BABCD6835Q33548211-C6886C7B-8457-45BD-A9BC-5BB3BBFBFEDDQ33648996-EFC6DE01-96FA-4961-B8F3-FCFAC5F62E34Q33669457-A5ABAECF-B64A-4B9A-BE41-4C065BD30252Q33770299-87EA6A6F-104A-44A0-8CCB-0695DD0E275AQ33783119-9404B720-F149-4015-8300-B74A93F67B59Q33895557-83E509FD-FA91-4B7B-B870-E44C6AE95342Q33948026-37DBE8F4-064F-4097-814F-A3713138F95EQ34013901-CEF2C542-CA11-42C7-9AA3-2F01A012B357Q34063746-567FD88F-9557-4905-BB45-A421FE42136FQ34248487-4BB39E88-EDE6-4FBB-9007-A01BB820F11BQ34256413-8EC2E66D-230A-4348-9F1A-CEABD1601FEFQ34283282-6E0E533A-56A7-4E31-BAD6-9D05593AF7DBQ34306680-5DD25F5A-202B-4647-A702-C2C91DD55E74Q34409477-3FD9D3E6-B89E-48DE-88D2-1FFCE7485162Q34414279-DBA1C0C9-4421-4C41-A633-6F6120D9F5FEQ34452319-6D1E03AA-927A-4F8C-8AFC-D2CAA4F5505CQ34484273-FDC78BA7-0284-44E6-A75D-14CC89E92539Q34495609-209141CA-41E4-4A64-931C-656F5F5BE838Q34498450-276165A5-298D-48FD-8FCC-2CF7FFE4E45BQ34564262-DDE7A056-1845-47EC-8E5F-ADCB49A371B9Q34573056-C598943E-62CD-415F-B251-3C2DF1AC2A07Q34731699-EBBBA823-47E1-4836-9648-F22A62ED9971Q34769975-23969406-4A2B-45C0-90AE-E017706A2452Q34829185-2FFB99B7-EEFA-4285-96B7-7C2488A313F4Q35001777-318C3AE5-71F0-4F55-9B8F-DD65CD201AE8
P2860
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@ast
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@en
type
label
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@ast
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@en
prefLabel
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@ast
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@en
P2093
P1433
P1476
Treatment of neuroendocrine ca ...... c variants of these neoplasms.
@en
P2093
P304
P356
10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I
P407
P577
1991-07-01T00:00:00Z